TORONTO, June 8, 2011 /PRNewswire/ - MEMOTEXT presented "The Impact of
Automated Dosing Reminders on Medication Adherence Using HealthVault,"
conducted by Johns Hopkins University and funded by the Microsoft
HealthVault Be Well Fund at Mobile Health 2011: What Really Works
conference at Stanford University May 4-5, 2011
Preliminary results from the Automated Dosing Reminder Study (ADRS) were
also presented at the March 2011 annual meeting of American Glaucoma
Of the 428 participants analyzed thus far, the study showed an increase
in adherence from 51 to 67% with daily glaucoma therapy using a
MEMOTEXT adherence solution integrated with Microsoft HealthVault. A
control group with no intervention showed no change in adherence. The
study to be published this year demonstrates efficacy of MEMOTEXT
solutions integrated with a personal health record.
"We are extremely pleased with the results of this adherence study."
says Amos Adler, president of MEMOTEXT. "Working with Dr. Boland and
his team helped make this a success and we are proud of the impact this
will have on the future of adherence and people living with glaucoma."
About Glaucoma and Adherence
Glaucoma is the second leading cause of blindness and visual disability
worldwide. It's estimated that 2.5 million people in the U.S. are
affected by glaucoma, with another 10 million undiagnosed. According to
the Glaucoma Research Foundation, there are currently 70 million people
worldwide who have been affected by glaucoma. Currently, there is no
cure for glaucoma. However, studies have shown that reducing the eye
pressure with topical medical therapy, office laser or surgery can
prevent occurrence or slow disease progression. The majority of
patients diagnosed with glaucoma or ocular hypertension are managed
initially with medications. However, despite the availability of
effective topical therapies, non-adherence in patients with glaucoma is
poor and has been reported between 37-59%.
The leader in speech, social and mobile, medication compliance
interventions, MEMOTEXT integrates behavior modification, education and
real time support into the everyday lives of patients using technology
appropriate to the patient population and condition. MEMOTEXT's ability
to learn and remember previously reported knowledge, intentions, and
behaviors allow the treatment medication compliance platform to modify
content and dialogues for the same individual over time.
SOURCE MEMOTEXT Personalized Adherence Solutions